Non-Hodgkin's lymphoma

Patients diagnosed 1993-2019 (ICD10: C82-C86)

Further information

Further data is available at: **www.qub.ac.uk/research-centres/nicr** Phone: +44 (0)28 9097 6028 e-mail: nicr@qub.ac.uk

Acknowledgements

The Northern Ireland Cancer Registry (NICR) is funded by the Public Health Agency and is based in Queen's University, Belfast. NICR uses data provided by patients and collected by the health service as part of their care and support.

The incidence, prevalence and survival statistics in this publication are designated as official statistics signifying that they comply with the Code of Practice for Official Statistics.



Incidence

During 2015-2019:

- There were 195 male and 151 female cases of non-Hodgkin's lymphoma diagnosed each year.
- Non-Hodgkin's lymphoma made up 3.9% of all male, and 3.1% of all female cancers (ex NMSC).
- The risk of developing non-Hodgkin's lymphoma before the age of 75 was 1 in 71.6 for men and 1 in 109.0 for women, while before the age of 85 the risk was 1 in 40.2 for men and 1 in 60.2 for women.

Incidence by age at diagnosis - Non-Hodgkin's lymphoma, Cases in 2015-2019


During 2015-2019:

• The median age at diagnosis was 69 for men and 72 for women.

• Cancer risk increased with age, with 30.3% of men and 39.7% of women aged 75 years or more at diagnosis.

• 16.5% of cases were diagnosed among those aged under 55.

Age at	Average cases per year							
diagnosis	Male	Female	Both sexes					
0 - 54	37	21	57					
54 - 64	41	24	64					
65 - 74	58	46	104					
75 +	59	60	119					
All ages	195	151	346					




Incidence by year of diagnosis - Non-Hodgkin's lymphoma, Cases in 1995-2019

• Among males the number of cases of non-Hodgkin's lymphoma increased by 10.8% from an annual average of 176 cases in 2010-2014 to 195 cases in 2015-2019.

• Among females the number of cases of non-Hodgkin's lymphoma decreased by 1.3% from an annual average of 153 cases in 2010-2014 to 151 cases in 2015-2019.

Year of diagnosis	Male	Female	Both sexes
2010	164	157	321
2011	191	166	357
2012	178	138	316
2013	168	135	303
2014	181	171	352
2015	182	150	332
2016	193	152	345
2017	204	157	361
2018	203	158	361
2019	191	139	330




Note: Annual averages have been rounded to the nearest integer. Sums of numbers in table rows or columns may thus differ slightly from the given total. NMSC: Non-melanoma skin cancer

Trends in age-standardised incidence rates - Non-Hodgkin's lymphoma, Cases in 1995-2019

 Among males age-standardised incidence rates of non-Hodgkin's lymphoma decreased by 3.4% from 26.6 per 100,000 person years in 2010-2014 to 25.7 cases per 100,000 persons years in 2015-2019. This difference was not statistically significant.

• Among females age-standardised incidence rates of non-Hodgkin's lymphoma decreased by 8.9% from 19.0 per 100,000 person years in 2010-2014 to 17.3 cases per 100,000 persons years in 2015-2019. This difference was not statistically significant.



Age-standardised incidence rates illustrate the change in the number of cases within a population of a fixed size and age structure (2013 European Standard).

They thus represent changes other than those caused by population growth and/or ageing.

Trends can also be influenced by changes in how cancer is classified and coded. (e.g. the move from ICD-0-2 to ICD-0-3 in 2019).

Incidence by deprivation quintile - Non-Hodgkin's lymphoma, Cases in 2015-2019

The annual number of cases during 2015-2019 varied in each deprivation quintile due to variations in population size and age.

After accounting for these factors, incidence rates:

• in the most socio-economically deprived areas did not vary significantly from the NI average.


• in the least socio-economically deprived areas did not vary significantly from the NI average.

Deprivation quintile	Average cases per year					
Deprivation quintile	Male	Female	Both sexes			
Least deprived (Quintile 1)	45	45 35				
Quintile 2	42	32	74			
Quintile 3	41	31	72			
Quintile 4	37	31	68			
Most deprived (Quintile 5)	30	23	53			
Northern Ireland	195	151	346			

Standardised incidence ratios compare incidence rates in each deprivation quintile with the Northern Ireland incidence rate.

A value above 100 means that incidence rates in that deprivation quintile are greater than the Northern Ireland average.

This measure takes account of population size and age structure. Differences are thus not a result of these factors.




Incidence by Health and Social Care Trust (HSCT) - Non-Hodgkin's lymphoma, Cases in 2015-2019

The annual number of cases during 2015-2019 varied in each HSCT due to variations in population size and age.

After accounting for these factors, incidence rates:

- in Belfast HSCT did not vary significantly from the NI average.
- in Northern HSCT did not vary significantly from the NI average.
- in South-Eastern HSCT did not vary significantly from the NI average.
- in Southern HSCT did not vary significantly from the NI average.
- in Western HSCT did not vary significantly from the NI average.



Health and Social Average cases per year Care Trust Male Female Both sexes Belfast HSCT 33 26 59 **Northern HSCT** 59 42 100 South-Eastern HSCT 39 30 69 Southern HSCT 33 30 64 Western HSCT 30 24 54 **Northern Ireland** 195 151 346

> Standardised incidence ratios compare incidence rates in each HSC Trust with the Northern Ireland incidence rate. A value above 100 means that incidence rates in that HSC Trust are greater than the NI average.

This measure takes account of population size and age structure. Differences are thus not a result of these factors.

Data for Local Government Districts and Parliamentary Constituencies are available at www.qub.ac.uk/researchcentres/nicr

Incidence by method of most recent admission to hospital - Non-Hodgkin's lymphoma, Cases in 2015-2019


During 2015-2019:

 22.4% of cases had an emergency admission to hospital recorded up to 30 days prior to their cancer diagnosis.

 22.8% of male cases had an emergency admission up to 30 days prior to diagnosis, compared to 21.8% of female cases.

• In 42.3% of diagnosed cases there was no record of a hospital inpatient admission up to 30 days prior to diagnosis.

-							
Method of admission	Average cases per year						
	Male	Female	Both sexes				
Emergency admission	44	33	77				
Elective admission	71	51	122				
No emergency/elective admission recorded	79	67	146				
Total	195	151	346				



Admission method refers to the most recent hospital inpatient admission that a patient had prior to cancer diagnosis, regardless of reason for the admission.

Admissions are considered up to a maximum of 30 days prior to diagnosis. Admissions up to two days post diagnosis are also considered to allow for a reasonable margin or error in data recording.

The majority of patients with no inpatient admission recorded prior to diagnosis are likely to have been diagnosed via an outpatient route.

Page 4 - Non-Hodgkin's lymphoma

Incidence by stage at diagnosis - Non-Hodgkin's lymphoma, Cases in 2015-2019


During 2015-2019:


85.6% of cases diagnosed had a stage assigned.

17.5% of cases were diagnosed at stage I. (20.5% of staged cases)

35.1% of cases were diagnosed at stage IV. (41.0% of staged cases)

• Among cases which were staged, 42.3% of male cases were diagnosed at stage IV, compared to 39.4% of female cases.





Cancer stage describes the size of a cancer and how far it has grown and spread.

This information is used to help decide what treatments are needed.


The classification used here to stage cancer is the TNM classification (Version 7 prior to 2018, Version 8 from 2018 onwards).

Survival

 73.9% of patients were alive one year and 56.9% were alive five years from a non-Hodgkin's lymphoma diagnosis in 2010-2014. (observed survival)

• Age-standardised net survival (ASNS), which removes the effect of deaths from causes unrelated to cancer, was 77.4% one year and 66.8% five years from a non-Hodgkin's lymphoma diagnosis in 2010-2014.


• Five-year survival (ASNS) for non-Hodgkin's lymphoma patients diagnosed in 2010-2014 was 64.1% among men and 69.8% among women.



Trends in survival - Non-Hodgkin's lymphoma, Patients diagnosed in 1995-2014

 Among men five-year survival (ASNS) from non-Hodgkin's lymphoma increased from 59.9% in 2005-2009 to 64.1% in 2010-2014. This difference was not statistically significant.

 Among women five-year survival (ASNS) from non-Hodgkin's lymphoma increased from 66.5% in 2005-2009 to 69.8% in 2010-2014. This difference was not statistically significant.




Survival by age at diagnosis - Non-Hodgkin's lymphoma, Patients diagnosed in 2010-2014

 Survival from non-Hodgkin's lymphoma among patients diagnosed in 2010-2014 was strongly related to age with five-year survival decreasing as age increases.


 Five-year net survival ranged from 83.8% among patients aged 15 to 54 at diagnosis to 48.3% among those aged 75 and over.

• Five-year net survival among patients aged 75 and over was 46.2% for men and 50.7% for women.



Survival by method of most recent admission to hospital - Non-Hodgkin's lymphoma, Patients diagnosed in 2010-2014

 Five-year survival (ASNS) among non-Hodgkin's lymphoma patients who had an emergency admission to hospital up to 30 days prior to their cancer diagnosis was 50.1% compared to 74.5% among those with elective admissions and 68.3% among those who had no hospital admissions recorded up to 30 days prior to diagnosis.




Survival by stage at diagnosis - Non-Hodgkin's lymphoma, Patients diagnosed in 2012-2014

 Stage at diagnosis is one of the most important factors in non-Hodgkin's lymphoma survival with five-year survival decreasing as stage increases.

 Five-year survival (ASNS) ranged from 80.0% for early stage (stage I) disease to 56.0% for late stage (stage IV) disease.

• Five-year survival (ASNS) for unstaged cancer was 63.9%.



Note: Staging information for non-Hodgkin's lymphoma is only available from 2012 onwards.

Prevalence

• At the end of 2019, there were 3,038 people (Males: 1,597; Females: 1,441) living with non-Hodgkin's lymphoma who had been diagnosed with the disease during 1995-2019.

25-year prevalence refers to the number of cancer survivors who were alive at the end of 2019, and had been diagnosed with their cancer in the previous 25 years (i.e. 1995-2019).

• Of these, 52.6% were male, 35.7% were aged 75 and over, and 9.3% had been diagnosed in the previous year.

Time since diagnosis	25-year prevalence										
	Aged 0-74				Aged 75+		All ages				
ulagnosis	Male	Female	Both sexes	Male	Female	Both sexes	Male	Female	Both sexes		
0-1 year	122	75	197	41	46	87	163	121	284		
1-5 years	356	234	590	185	157	342	541	391	932		
5-10 years	269	237	506	125	167	292	394	404	798		
10-25 years	360	300	660	139	225	364	499	525	1,024		
0-25 years	1,107	846	1,953	490	595	1,085	1,597	1,441	3,038		

Trends in 10-year prevalence - Non-Hodgkin's lymphoma, Patients alive at end of each year from 2010-2019

• Among males the number of survivors from non-Hodgkin's lymphoma who had been diagnosed within the previous ten years increased by 20.3% from 913 survivors in 2014 to 1,098 survivors in 2019.

• Among females the number of survivors from non-Hodgkin's lymphoma who had been diagnosed within the previous ten years increased by 6.0% from 864 survivors in 2014 to 916 survivors in 2019.

	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Male	753	803	845	877	913	926	973	1,003	1,064	1,098
Female	776	804	824	836	864	870	889	890	916	916
Both sexes	1,529	1,607	1,669	1,713	1,777	1,796	1,862	1,893	1,980	2,014

Mortality

- During 2015-2019 there were 64 male and 58 female deaths from non-Hodgkin's lymphoma each year.
- Non-Hodgkin's lymphoma made up 2.8% of all male, and 2.8% of all female cancer deaths (ex NMSC).

Deaths by age at death - Non-Hodgkin's lymphoma, Deaths in 2015-2019

• The median age at death during 2015-2019 was 75 for men and 79 for women.

 Risk of death from non-Hodgkin's lymphoma was strongly related to age, with 50.0% of men and 63.8% of women aged 75 years or more at time of death.

• 6.6% of non-Hodgkin's lymphoma deaths occurred among those aged under 55.

Age at	Average deaths per year							
Age at death	Male	Female	Both sexes					
0 - 54	5	3	8					
55 - 64	7	3	10					
65 - 74	20	13	33					
75 +	32	37	69					
All ages	64	58	122					

Deaths by year of death - Non-Hodgkin's lymphoma, Deaths in 2010-2019

• Among males the number of deaths from non-Hodgkin's lymphoma decreased by 3.0% from an annual average of 66 deaths in 2010-2014 to 64 deaths in 2015-2019.


• Among females the number of deaths from non-Hodgkin's lymphoma decreased by 1.7% from an annual average of 59 deaths in 2010-2014 to 58 deaths in 2015-2019.

	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Male	69	75	71	48	67	78	60	64	57	62
Female	53	58	60	59	66	62	55	63	61	48
Both sexes	122	133	131	107	133	140	115	127	118	110

Trends in age-standardised mortality rates - Non-Hodgkin's lymphoma, Deaths in 1995-2019

Among males age-standardised mortality rates from non-Hodgkin's lymphoma decreased by 15.3% between 2010-2014 and 2015-2019 from 11.1 to 9.4 deaths per 100,000 persons years. This difference was not statistically significant.

• Among females age-standardised mortality rates from non-Hodgkin's lymphoma decreased by 11.0% between 2010-2014 and 2015-2019 from 7.3 to 6.5 deaths per 100,000 persons years. This difference was not statistically significant.



Mortality data are provided by the Northern Ireland General Registrar Office via the Department of Health.

Counts of the number of deaths are based upon the year that death occurred, and upon the primary cause of death only.

Age-standardised mortality rates remove changes over time caused by population growth and/or ageing.

Background notes

<u>Cancer classification</u>: Classification of tumour sites is carried out using ICD10 codes. For a listing and explanation of ICD10 codes see: World Health Organisation at http://apps.who.int/classifications/icd10/browse/2010/en#/II

Population data for Northern Ireland, and smaller geographic areas, are extracted from the NI mid-year population estimates available from the NI Statistics and Research Agency (available at www.nisra.gov.uk).

<u>Geographic areas</u> are assigned based on a patient's postcode of usual residence at diagnosis using the Jan 2021 Central Postcode Directory (CPD) produced by the NI Statistics and Research Agency (available at www.nisra.gov.uk).

Deprivation quintiles: Super output areas (SOA) are assigned to each patient based on their postcode of usual residence at diagnosis. Using the SOA each patient is assigned a socio-economic deprivation quintile based on the 2017 Multiple Deprivation Measure. The 2017 Multiple Deprivation Measure is available from the NI Statistics and Research Agency (available at www.nisra.gov.uk).

A <u>crude incidence/mortality rate</u> is the number of cases/deaths per 100,000 person years in the population. Person years are the sum of the population over the number of years included.

An <u>age-standardised incidence/mortality rate</u> per 100,000 person years is an estimate of the incidence/mortality rate if that population had a standard age structure. Throughout this report the 2013 European Standard Population has been used. Standardising to a common Standard Population allows comparisons of incidence/mortality rates to be made between different time periods and geographic areas while removing the effects of population change and ageing.

A <u>Standardised Incidence/Mortality Ratio (SIR/SMR)</u> is the ratio of the number of cases/deaths observed in a population to the expected number of cases/deaths, based upon the age-specific rates in a reference population. This statistic is often used to compare incidence/mortality rates for geographic areas (e.g. Trusts) to the national incidence/mortality rates (i.e. Northern Ireland). An SIR/SMR of 100 indicates there is no difference between the geographic area and the national average.

<u>Confidence intervals</u> are a measure of the precision of a statistic (e.g. colorectal cancer incidence rate). Typically, when numbers are low, precision is poorer and confidence intervals will be wider. As a general rule, when comparing statistics (e.g. cervical cancer incidence rate in year 2012 vs year 2013), if the confidence interval around one statistic overlaps with the interval around another, it is unlikely that there is any real difference between the two. If there is no overlap, the difference is considered to be <u>statistically significant</u>.

<u>Lifetime risk</u> is estimated as the cumulative risk of getting cancer up to age 75/85, calculated directly from the age-specific incidence rates. The odds of developing the disease before age 75/85 is the inverse of the cumulative risk.

<u>Prevalence</u> is the number of cancer patients who are alive in the population on a specific date (31st December 2019 in this report). Since data from the NI Cancer Registry are only available since 1993, prevalence only refers to a fixed term (10 and 25 years in this report). There may be members of the population living with a diagnosis of cancer for more than 25 years.

Observed survival refers to the proportion of patients who survive a specified amount of time from their date of diagnosis. Observed survival considers death from any cause and is not adjusted for the age of the patient. Cause of death may be unrelated to the cancer the patient has been diagnosed with.

Net Survival is an estimate of survival where the effect on survival of background population mortality rates has been removed. It represents the [theoretical] survival of cancer patients if they could only die from cancer-related causes. Age-standardised net survival estimates are the estimates that would occur if that population of cancer patients had a standard population age structure. The age groups and weights used here are those used by international studies such as EUROCARE, an international study group that compares cancer survival among European countries. However, due to the small number of patients in NI, the first two age categories in the standard population are combined.

<u>Mortality</u>: Information relating to cancer mortality is sourced from the General Registrar Office (GRONI) via the Department of Health (NI). Results are based upon the date on which death occurs, and may thus differ slightly than those produced by the Northern Ireland Statistics and Research Agency (NISRA), which produces deaths data based upon the date on which the death is registered with GRONI.